Drug Type Small molecule drug |
Synonyms Syk inhibitor, BIIB-057, P 50515 + [4] |
Target |
Action inhibitors |
Mechanism Syk inhibitors(Spleen tyrosine kinase inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC19H23N9O |
InChIKeyTXGKRVFSSHPBAJ-JKSUJKDBSA-N |
CAS Registry1370261-96-3 |
Start Date01 Aug 2012 |
Sponsor / Collaborator |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Rheumatoid Arthritis | Phase 2 | Canada | 01 Aug 2012 | |
Inflammation | Phase 1 | United States | - | |
Inflammation | Phase 1 | United Kingdom | - | |
Neoplasms | Phase 1 | United States | - | |
Neoplasms | Phase 1 | United Kingdom | - | |
Systemic Lupus Erythematosus | Phase 1 | United States | - | - |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
No Data |